208 related articles for article (PubMed ID: 18055856)
1. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
Tascilar M; Loos WJ; Seynaeve C; Verweij J; Sleijfer S
Oncologist; 2007 Nov; 12(11):1351-60. PubMed ID: 18055856
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE
J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Hartmann JT
Anticancer Drugs; 2007 Mar; 18(3):245-54. PubMed ID: 17264755
[TBL] [Abstract][Full Text] [Related]
5. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy in adult soft tissue sarcoma.
Jain A; Sajeevan KV; Babu KG; Lakshmaiah KC
Indian J Cancer; 2009; 46(4):274-87. PubMed ID: 19749457
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas.
Casali P; Pastorino U; Azzarelli A; Bertulli R; Zucchinelli P; Devizzi L; Santoro A
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S228-32. PubMed ID: 8453704
[TBL] [Abstract][Full Text] [Related]
8. New therapies in soft tissue sarcoma.
Vincenzi B; Frezza AM; Santini D; Tonini G
Expert Opin Emerg Drugs; 2010 Jun; 15(2):237-48. PubMed ID: 20465449
[TBL] [Abstract][Full Text] [Related]
9. Novel treatment strategies for soft tissue sarcoma.
Kasper B; Gil T; D'Hondt V; Gebhart M; Awada A
Crit Rev Oncol Hematol; 2007 Apr; 62(1):9-15. PubMed ID: 17141519
[TBL] [Abstract][Full Text] [Related]
10. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathology and potential therapeutic targets in soft-tissue sarcoma.
Todd R; Lunec J
Expert Rev Anticancer Ther; 2008 Jun; 8(6):939-48. PubMed ID: 18533803
[TBL] [Abstract][Full Text] [Related]
12. The use of hematological growth factors to enable dose intensification in chemotherapy for soft tissue sarcomas.
Liem GS; Verweij J
Stem Cells; 1994 Jul; 12(4):402-8. PubMed ID: 7951007
[TBL] [Abstract][Full Text] [Related]
13. Role of chemotherapy in patients with soft tissue sarcomas.
Maki RG
Expert Rev Anticancer Ther; 2004 Apr; 4(2):229-36. PubMed ID: 15056053
[TBL] [Abstract][Full Text] [Related]
14. Palifosfamide, a bifunctional alkylator for the treatment of sarcomas.
Jung S; Kasper B
IDrugs; 2010 Jan; 13(1):38-48. PubMed ID: 20024846
[TBL] [Abstract][Full Text] [Related]
15. Salvage therapy for soft tissue sarcomas.
Elias AD
Semin Oncol; 1994 Aug; 21(4 Suppl 7):76-81. PubMed ID: 8091245
[TBL] [Abstract][Full Text] [Related]
16. New emerging drugs in soft tissue sarcoma.
Milano A; Apice G; Ferrari E; Fazioli F; de Rosa V; de Luna AS; Iaffaioli RV; Caponigro F
Crit Rev Oncol Hematol; 2006 Jul; 59(1):74-84. PubMed ID: 16533604
[TBL] [Abstract][Full Text] [Related]
17. Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge?
Kasper B; Gil T; Awada A
Curr Opin Oncol; 2007 Jul; 19(4):336-40. PubMed ID: 17545796
[TBL] [Abstract][Full Text] [Related]
18. In vitro chemosensitivity of human soft tissue sarcoma.
Morioka H; Yabe H; Morii T; Yamada R; Kato S; Yuasa S; Yano T
Anticancer Res; 2001; 21(6A):4147-51. PubMed ID: 11911309
[TBL] [Abstract][Full Text] [Related]
19. Comparison of doxorubicin with cycloleucine in the treatment of sarcomas.
Savlov ED; MacIntyre JM; Knight E; Wolter J
Cancer Treat Rep; 1981; 65(1-2):21-7. PubMed ID: 7013976
[TBL] [Abstract][Full Text] [Related]
20. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
